AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its 'off-the-shelf' Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic
'Immunotherapy was clearly a central focus at AACR 2025, with growing recognition across the scientific community that cancer vaccines are now a promising strategy for both treatment and prevention.' said George Alzeeb, PhD, Innovation Manager at Brenus Ph
Share
The data highlight advances from Brenus Pharma's proprietary Stimulated-Tumor-Ghost Cell (SGC) platform, a next-generation precision immuno-oncology approach showcasing its potential to initiate a robust anti-tumor response in colorectal cancer—a major unmet need in solid tumors.
Key findings demonstrate the reproducibility of STC-1010's anti-tumor profile across multiple manufacturing batches and preclinical models (in vivo, in ovo, ex vivo) including those modified to be resistant to current immunotherapies. Dendritic cells showed increased antigen presentation and activation of CD8⁺ T cells with STC-1010, resulting in significant tumor cell apoptosis (tumor killing) and reduced metastasis.
'Immunotherapy was clearly a central focus at AACR 2025, with growing recognition across the scientific community that cancer vaccines are now a promising strategy for both treatment and prevention.' said George Alzeeb, PhD, Innovation Manager at Brenus Pharma. 'We're proud to be part of this momentum and look forward to the next steps.'
Title: ' Preclinical efficacy of an innovative therapeutic cancer vaccine: a new era for immunotherapy ' LB383 – Session: Late-Breaking Research: Immunology 3 [ poster ]
Authors:
George Alzeeb¹, Iseulys Richert¹, Corentin Richart², Paul Marteau³, Lionel Chalus¹, Marion Brun¹, Yan Wan⁴, Corinne Tortorelli¹, Benoit Pinteur¹, Paul Bravetti¹, Céline Gongora⁵, Antoine Italiano⁶, François Ghiringhelli⁷
¹Brenus Pharma – ²ICMUB UMR CNRS 6302 – ³Explicyte – ⁴Inovotion – ⁵INSERM U1194 – ⁶Institut Bergonié – ⁷INSERM UMR1231
About us:
Brenus' off-the-shelf platform empowers immune cells in vivo to fight cancer by mimicking cancer nature and making it visible to the immune system. We are developing a solid tumor pipeline leveraging our proprietary next-generation precision platform and making patient once again actor in their treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Helix Energy Solutions Awarded Multi-Year Contract in the Gulf of America
HOUSTON--(BUSINESS WIRE)--Helix Energy Solutions Group, Inc. (NYSE: HLX) announced today that it has been awarded a multi-year contract with a major operator to provide production enhancement and well abandonment services in the U.S. Gulf of America. The contract, commencing in 2026, includes a minimum commitment of vessel utilization, split over three years. The contract calls for the provision of either the Q5000 or Q4000 riser-based well intervention vessel, a 10k or 15k Intervention Riser System (IRS) and remotely operated vehicles as well as project management and engineering services. Our services cover operations from fully integrated production enhancement to fully integrated plug and abandonment well services. The contract includes equipment and services as part of our Subsea Services Alliance, a strategic partnership between Helix and SLB that combines our collective strengths to deliver industry-leading subsea solutions. Scotty Sparks, Helix's Executive Vice President and Chief Operating Officer, stated, 'We are pleased to expand our backlog by successfully executing another multi-year contract for well intervention services. This contract underscores our commitment to delivering safe, cost-effective and efficient production enhancement and abandonment services in the Gulf of America, supported by Helix's advanced vessels, decades of industry-leading experience, and the collaborative capabilities of our Subsea Services Alliance.' About Helix Helix Energy Solutions Group, Inc., headquartered in Houston, Texas, is an international offshore energy services company that provides specialty services to the offshore energy industry, with a focus on well intervention, robotics and decommissioning operations. Our services are key in supporting a global energy transition by maximizing production of existing oil and gas reserves, decommissioning end-of-life oil and gas fields and supporting renewable energy developments. For more information about Helix, please visit our website at About Subsea Services Alliance For more information about the Subsea Services Alliance, please visit its website at Forward-Looking Statements This press release contains forward-looking statements that involve risks, uncertainties and assumptions that could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, any statements regarding the agreement, the equipment and services thereunder and the parties thereto; the current market or demand for our services; our ability to enter into, renew and/or perform commercial contracts; our current work continuing; and any impact on our financial and operating results and estimates; any statements regarding our strategy; any statements regarding our business model or the global energy transition; and any statements of assumptions underlying any of the foregoing. The forward-looking statements are subject to a number of known and unknown risks, uncertainties and other factors that could cause results to differ materially from those in the forward-looking statements, including but not limited to the terms of the agreement and/or any work thereunder or extension thereof; actions by governments, customers, suppliers and partners; market conditions; demand for our services; the performance of contracts by suppliers, customers and partners; actions by governmental and regulatory authorities; operating hazards and delays, which includes delays in delivery, chartering or customer acceptance of assets or terms of their acceptance; our ultimate ability to realize current backlog; employee management issues; complexities of global political and economic developments; geologic risks; volatility of oil and gas prices and other risks described from time to time in our reports filed with the Securities and Exchange Commission (the 'SEC'), including Helix's most recently filed Annual Report on Form 10-K and in Helix's other filings with the SEC, which are available free of charge on the SEC's website at We assume no obligation and do not intend to update these forward-looking statements, which speak only as of their respective dates, except as required by the securities laws.
Business Wire
2 hours ago
- Business Wire
Shareholder Alert: The Ademi Firm investigates whether Guess Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Guess (NYSE: GES) for possible breaches of fiduciary duty and other violations of law in its transaction with Authentic Brands and the co-founders. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Guess will receive $16.75 per share in cash or approximately $1.4 billion, including debt. Guess insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Guess by imposing a significant penalty if Guess accepts a competing bid. We are investigating the conduct of the Guess board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
2 hours ago
- Business Wire
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of AVITA Medical, Inc. ('Avita' or the 'Company') (NASDAQ: RCEL) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AVITA MEDICAL, INC. (RCEL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 7, 2025, Avita released its second quarter 2025 financial results, revealing 'a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.' The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company's wound care product, Recell, 'neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.' As a result, 'claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for RECELL procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in RECELL utilization during the first half of the year.' On this news, Avita's stock price fell $1.13, or 21%, to close at $4.25 per share on August 8, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Avita securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
